CTI's Pixuvri wins French reimbursement despite "weak" medical benefit
This article was originally published in Scrip
Executive Summary
Cell Therapeutics' Pixuvri (pixantrone) has scraped through the French health technology appraisal process, offering "weak" medical benefit, and "no therapeutic progress", according to French HTA authorities. Nevertheless, CTI remains upbeat and is working to get the drug on the reimbursement list for hospitals.